. Patients were monitored for regimen-related toxicity, engraftment, supportive care, response and survival. Both groups underwent ASCT at a median of 8 months from diagnosis and were matched for disease characteristics, prior therapy and pre-ASCT disease responsiveness. Amifostine infusional side-effects were frequent, occurring in 65% of patients, but of mild severity. Amifostine use was associated with a reduction in the median grade of oral mucositis (1 vs 2, P ¼ 0.01) and the frequency of severe (WHO grades 3 or 4) mucositis (12 vs 33%, P ¼ 0.02), but no reduction in the requirement for parenteral nutrition or analgesic use. Conversion to complete remission post-ASCT occurred in 30 and 14% of the amifostine and control groups, respectively (P ¼ 0.09). With a median follow-up of 35 months, there was no statistically significant difference between the median progression-free or overall survival times for the two groups. We conclude that amifostine can be safely administered prior to highdose melphalan and significantly reduces the frequency and severity of therapy-induced oral mucositis. Multiple myeloma (MM) is a common haematological malignancy of the bone marrow plasma cells that remains incurable. Median survival with standard dose chemotherapy is about 3 years and has not changed significantly in the last 20 years. 1 High-dose melphalan improves disease response rates even in patients with resistant MM; 2, 3 however, marrow function is slow to recover, resulting in prolonged periods of cytopenia and treatment-related mortality (TRM) of up to 20%. 3 High-dose chemotherapy with melphalan (with or without total body irradiation) supported by autologous stem cell transplantation (ASCT) has been shown in randomised multicentre trials to improve complete remission (CR) rates and survival when compared to standard dose chemotherapy, and to be associated with acceptable rates of toxicity. 4, 5 Based on these observations, ASCT is now regarded as the 'gold standard' for younger, fitter patients with MM. More recently, registry data from the EBMT and a randomised IFM trial suggest that melphalan 200 mg/m 2 (Mel200) may be safer and more effective than total body irradiation (TBI) containing conditioning regimens, and as such Mel200 has largely replaced TBI regimens as conditioning for ASCT. 6, 7 Mel200 is associated with dose-limiting nonhaematological toxicity principally of gastrointestinal origin (mucositis, nausea, vomiting, anorexia) but with little other extramedullary toxicity. 8 Predictably, attempts at increasing melphalan dosage above 200 mg/m 2 , while demonstrating obvious disease activity, have been associated with unacceptable rates of Grade IV mucositis and significant delays in platelet recovery. 9 Amifostine is a radioprotectant pro-drug that upon activation via dephosphorylation confers protection to normal but not malignant cells against oxygen-based radicals and electrophilic reactive drugs such as alkylator (nitrogen mustard, cyclophosphamide, melphalan) and organoplatinum anticancer drugs. [10] [11] [12] [13] [14] [15] [16] [17] In animal models amifostine produces a significant increase in resistance to haemopoietic injury from alkylating agents and the nephrotoxicity of cisplatin, without altering antitumour activity. 10, 14, 18 Laboratory data suggest that the mechanism of amifostine's selective protection is related to its preferential uptake in normal vs malignant tissues. 13, 19 This is in part due to the better vascularity, higher alkaline phosphatase levels (required for dephosphorylation of the prodrug to its active metabolite -the free thiol WR-1065), and the higher pH of normal tissue.
A single prospective randomised study in a high-dose chemotherapy setting has demonstrated that amifostine can significantly reduce severe mucositis, delayed emesis, days with fever and inpatient stay in patients receiving etoposide, ifosfamide and carboplatin (HD-VIC). 20 Furthermore, limited nonrandomised data suggest that amifostine may be effective in abrogating the gastrointestinal toxicities associated with high-dose melphalan. [21] [22] [23] A retrospective analysis showed that amifostine pretreated patients with MM or lymphoma going on to receive high-dose melphalan alone or in combination with other cytotoxics experienced significantly less severe mucositis, emesis and diarrhoea, when compared to a historical group of matched similarly treated patients. 21 Finally, a phase I/II dose-escalation study of amifostine has demonstrated that patients can be treated with doses of melphalan upto 280 mg/m 2 , with dose-limiting refractory atrial fibrillation occurring at 300 mg/m 2 . 24 Based on these observations, we have undertaken a multicentre randomised study of amifostine pretreatment in MM patients undergoing a first ASCT conditioned with Mel200. The study was designed to determine if amifostine could safely reduce the oral mucositis associated with Mel200 without diminishing the chemotherapeutic efficacy of the procedure.
Materials and methods

Study design
A multicentre open label randomised study was undertaken in 14 transplant units under the auspices of the Australasian Leukaemia and Lymphoma Group (ALLG). Patients aged 18-70 years with a diagnosis of MM undergoing a first ASCT procedure with ECOG p2, adequate renal and hepatic function (within 1.5 Â the institutional upper limit of normal) and with at least 2 Â 10 6 CD34 þ cells/kg body weight were eligible. Patients were randomised to receive Mel200 with or without amifostine 910 mg/m 2 pretreatment 15-30 min prior to melphalan infusion. Patients were stratified by centre. All patients were planned to receive interferon alpha-2b 3.0 Â 10 6 units thrice weekly from day 48 post-ASCT if stable haemopoietic engraftment had occurred. Patients were monitored for toxicity, supportive care, engraftment, disease response and survival.
Treatment plan and supportive care
Patients received antiemetic premedication with dexamethasone 20 mg i.v. and a standard dose of a 5HT 3 antagonist 30-60 min prior to amifostine administration.
Amifostine 910 mg/m 2 was reconstituted in 50 ml normal saline and given as a continuous infusion over 15 min with patients supine. Blood pressure was measured prior to, every 2 min during and at 5 min following completion of the infusion. As per previously published guidelines, the protocol stipulated the degree of hypotension mandating infusion interruption. 25 In the event of hypotension, patients were kept supine and administered a rapid infusion of saline until the blood pressure recovered. If the blood pressure recovered to above the interruption threshold within 5 min and the patient remained asymptomatic, the infusion was recommenced. If necessary, this process was repeated to enable completion of the infusion. If the blood pressure did not recover within 5 min, the infusion was abandoned. Mel200 was planned to be administered i.v. over 30 min within 30 min of completion of the amifostine infusion.
All patients received antibacterial prophylaxis with ciprofloxacin 500 mg bd or norfloxacin 400 mg bd commencing 2 days prior to ASCT and continuing until the absolute neutrophil count (ANC) exceeded 1.0 Â 10 9 /l. Fluconazole 100 mg bd was administered for the same time period. The use of antiviral and anti-PCP prophylaxis was not stipulated. Empirical nonprophylactic antibacterials were commenced at the discretion of the attending physician in any patient experiencing a temperature 4381C at any time up until haemopoietic recovery. /l in the post-ASCT period. Toxicity was evaluated daily and graded with the adapted WHO toxicity scale. 26 Total parenteral nutrition (TPN) and parenteral narcotics were commenced at the discretion of the attending physician. Interferon alpha-2b was to be started at day þ 48 following ASCT at a dose of 3.0 Â 10 6 units by subcutaneous injection thrice weekly if stable haemopoietic engraftment had occurred.
Statistical methods
Classification of pre-ASCT disease response, ASCT disease response and subsequent disease progression were based on previously published criteria. 27, 28 Based on the local data on file, it was estimated that the frequency of significant mucositis (grades 2, 3 and 4) with Mel200 would be 46%. It was therefore planned to accrue 90 patients, thus providing a greater than 80% power to detect a reduction in significant mucositis of 27%, that is, from 46 to 19%. All categorical variables were compared using w 2 statistics. Comparison of toxicities between treatment arms was made using the t-test for independent samples. Times to platelet and neutrophil engraftment, progression-free and overall survival were compared using the method of KaplanMeier. Calculation of progression-free and overall survival was based on the time of last disease evaluation and contact with patients, respectively. All analyses were undertaken on an intent-to-treat basis. All p values reported are 2-sided and Po0.05 was considered significant. Statistical analyses were performed using Statistica for Macintosh Version 4.1 (StatSoft, Tulsa, OK, USA).
Results
Patient and disease characteristics
Between May 1999 and November 2000, 90 patients aged between 31 and 69 years were randomised to receive Mel200 with (n ¼ 43) or without (n ¼ 47) amifostine pretreatment. The groups were well matched in terms of patient and disease characteristics (Table 1) , prior therapy and pre-ASCT disease responsiveness ( Table 2 ). Median follow-up for surviving patients is 35 months (range 15-46).
Amifostine administration
Toxicities related to the amifostine infusion were common, occurring in 65% of patients (Table 3) . In all but one case (grade 3 hypotension) these were minor, and did not prevent completion of the infusion. In two further cases the high-dose melphalan was administered greater than 30 min post-amifostine infusion because of hypertension requiring medical assessment. Hypocalcaemia was not seen.
Post-ASCT engraftment and haematological toxicity
Details of CD34 doses, engraftment kinetics and blood product support are summarised in Table 4 . Times to neutropenia (o0.5 Â 10 9 /l) and thrombocytopenia (o20 Â 10 9 /l), and subsequent recovery of counts were not statistically different between the two groups. As such the median durations of severe neutropenia and thrombocytopenia were not statistically different, 5 and 3 days vs 5 and 4 days, respectively, for the control and amifostine groups. Likewise, there was no difference in the median number of red blood cell and platelet units transfused. Both groups experienced a median of 1 febrile day, range 0-10 and 0-15 days, and had similar requirements for nonprophylactic intravenous antibiotics, median 6 days (range 0-24) vs 5 days (range 0-50), for the control and amifostine groups, respectively. Amifostine prior to high-dose melphalan A Spencer et al
Nonhaematological toxicity and supportive care
There was no difference in the frequency or severity of nongastrointestinal toxicity between the two groups (data not shown). The severity and incidence of melphalaninduced mucositis experienced in the two arms are summarised in Table 5 . The use of amifostine was associated with a reduction in the median grade of maximal mucositis (1 vs 2, P ¼ 0.01) and the incidence of significant (grades 2, 3 or 4) (44 vs 67%, P ¼ 0.03) and severe (grades 3 or 4) mucositis (12 vs 33%, P ¼ 0.02) (Figure 1) , when compared to the control group. Likewise, the likelihood of experiencing no mucositis was higher in the amifostine group, 23 vs 11%, although this did not achieve statistical significance (P ¼ 0.12). For patients who suffered any grade of mucositis, the median duration of maximal severity was 3 days in the control group and 4 days in the amifostine group (P ¼ 0.18). The control group was more likely to suffer severe (grades 3 and 4) delayed emesis, 46 vs 30%, compared to the amifostine group, although this again did not achieve statistical significance (P ¼ 0.14). Despite the reduction in severe mucositis, there was no statistically significant difference in the requirement for or duration of TPN or parenteral narcotics (Table 4) .
ASCT response and survival
There were no ASCT-related deaths in either arm. In all, 82 patients (control group n ¼ 41, amifostine group n ¼ 40) were evaluable to determine post-ASCT disease response (six patients were in CR prior to ASCT and two patients had insufficient post-ASCT data), with 63% of patients in both groups achieving a further PR or CR in response to the ASCT procedure. The degree of response achieved appeared to be greater in the amifostine group with 30% (12 of 40) of patients converting to a CR (immunofixation negative) vs only 14% (six of 42) in the control group (P ¼ 0.09). Interferon-alpha was commenced in 56% of the amifostine group and in 53% of the control group post-ASCT. With a median follow-up of 35 months, there is no difference between the amifostine and control groups for progression-free survival (18 vs 21 months, respectively, P ¼ 0.40) (Figure 2) . Likewise, there is no statistical difference in overall survival (42 months vs not reached, respectively, P ¼ 0.23). However, these comparisons must be interpreted with caution as the study was specifically Table 4 Engraftment and supportive therapy 
Table 5
Melphalan-induced mucositis and supportive therapy powered to detect differences in the rates of significant mucositis, not survival. Furthermore, only 24 of the 90 patients have died and treatment approaches following progression were not mandated, being at the discretion of the attending physician.
Discussion
While high-dose chemotherapy and ASCT is presently the single most effective treatment modality for MM, it falls well short of providing an effective approach for a large proportion of patients. With a median age at diagnosis of greater than 60 years, possibly half or more of patients will be excluded from ASCT programmes, depending on local selection criteria. Furthermore, more than half of the patients undergoing ASCT will not achieve CR 4, 5, 29 and the attendant prolongation of survival that this confers. 30 Therefore, strategies to ameliorate melphalan-related toxicities that would enable both the use of ASCT in older patients or those with co-morbidities and the rational evaluation of further dose escalation in poor risk MM patients are desirable.
This randomised multicentre trial determined the effect of amifostine pretreatment on melphalan-associated toxicities in MM patients receiving high-dose single-agent melphalan. The amifostine administration, while commonly associated with minor infusional side-effects, was generally well tolerated with only one grade 3 toxicity in 43 patients. Moreover, despite the acute association of nausea and vomiting with amifostine, the trend to less delayed emesis is consistent with the reductions previously described in nonrandomised trials of amifostine prior to highdose melphalan. [21] [22] [23] More importantly, we have confirmed the observations from nonrandomised studies that amifostine significantly reduces both significant (grades 2, 3 or 4) and severe (grades 3 and 4) melphalan-induced mucositis ( Figure 1 , Table 5 ). This reduction was associated with a doubling from 11% (amifostine arm) to 23% (control arm) in the number of patients experiencing no mucositis (Figure 1 ). Despite the reduction in mucositis incidence and severity, we saw no reduction in the actual duration of the highest grade of mucositis (median 3 vs 4 days for control and amifostine groups, respectively, P ¼ 0.18) and this may well be one of the reasons underlying our failure to demonstrate a significant reduction in the supportive care required. Furthermore, the duration of TPN and narcotic support in the control group was brief (Table 5 ). It may be that reductions in supportive care may only be demonstrable when amifostine is used in combination with regimens associated with more prolonged and/or severe gastrointestinal toxicity, for example, melphalan 220 mg/m 2 or multi-agent high-dose chemotherapeutic regimens such as HD-VIC 9, 20 Work undertaken combining amifostine pre-and posttreatment with carboplatin in patients with various cancers has demonstrated a reduction in dose-limiting thrombocytopenia despite enhanced drug delivery 31, 32 Likewise, the severity and duration of neutropenia secondary to cyclophosphamide can be ameliorated by amifostine. 17 These effects would appear to be due principally to the ability of amifostine to protect haemopoietic progenitors from a range of chemotherapeutic agents, as shown by in vitro clonogenic assays 17, 33, 34 and further supported by engraftment data from a randomised trial of in vitro amifostine in the context of 4-HC purged bone marrow prior to transplantation. 35 This being the case, it is not surprising that we saw no differences in engraftment times or subsequent blood product support required when using myeloablative doses of melphalan as haemopoietic reconstitution was derived in both trial arms from reinfused progenitors that had not been exposed to conditioning chemotherapy. Our experience is consistent with data from uncontrolled trials of amifostine in combination with highdose melphalan, [21] [22] [23] but in contrast to the study published by Hartmann et al 20 using HD-VIC. The latter study demonstrated a statistically significant shortening of time to both neutrophil and platelet engraftment associated with a reduction in the incidence of febrile neutropenia but not blood product support requirements. This raises the possibility that amifostine may have both drug-and tissuespecific protective effects underlying the differences seen in engraftment outcomes. One could postulate protection of nonhaemopoietic bone marrow elements and more rapid haemopoietic recovery occurring when amifostine is combined with some drugs (HD-VIC), but not when combined with others (Mel200).
Within the context of the previously described limitations, there was no evidence for either an immediate or delayed adverse impact of amifostine pretreatment on disease responsiveness to Mel200. On the contrary, a greater proportion of patients in the amifostine arm were converted to CR than in the control arm (14% control arm, 30% amifostine arm, P ¼ 0.09). Although it could be argued that the CR conversion rate in the control arm is somewhat lower than what would have been expected with Mel200, it is apparent that high-dose melphalan with amifostine is at least as effective as high-dose melphalan alone. This notion is further supported by the equivalent durations of PFS experienced by the two treatment groups (21 months control arm vs 18 months amifostine arm, P ¼ 0.4, log rank). The observed CR conversion rate is not inconsistent with in vitro observations, suggesting that amifostine may lead to sensitisation of malignant cells, resulting in an enhanced likelihood of genotoxicity following subsequent exposure to melphalan. 34 Overall, as expected, the impact of attaining CR was highly significant with a median PFS for patients in CR post-ASCT of 30 months, but only 17 months for the remainder (P ¼ 0.003).
These data are consistent with observations in the limited number of randomised studies that have evaluated disease response and duration of response when using amifostine pretreatment. The largest of these studies evaluated amifostine-induced abrogation of toxicities in women treated with cyclophosphamide and cisplatin for advanced ovarian carcinoma. 16 Of those women who underwent a second-look surgery to assess response, 75% (45 of 60) in the amifostine arm vs 65% (34 of 52) in the control group achieved a partial or complete response. Progression-free and overall survivals were comparable in both groups. Similarly, a smaller randomised trial of cyclical carboplatin therapy with or without amifostine for advanced nonsmall-cell lung cancer showed response rates and median durations of overall survival of 50 vs 22%, and 14 vs 9 months for the amifostine and control groups, respectively. 31 In the only published randomised study of amifostine in the setting of high-dose therapy, no data describing disease responsiveness or survival were reported. 20 The results of this randomised study demonstrate that amifostine at a dose of 910 mg/m 2 can be safely given prior to high-dose melphalan conditioning in patients with MM undergoing ASCT. Furthermore, the use of amifostine is associated with a significant reduction in the severity of melphalan-induced oral mucositis. These data provide a rationale for the inclusion of amifostine pretreatment in the evaluation of further melphalan dose escalation for poor risk myeloma patients undergoing ASCT and the consideration of incorporating amifostine into conditioning strategies for patients who previously may have been considered unsuitable for ASCT.
